The synergy was linked with the reprogramming of peritumoral stromal fibroblasts (CAF) and increased CD8+ T-effector cells within the tumor, leading to resensitization/anti-tumor immunity to atezolizumab [141]. The gene discussed is CD8A; the disease is neoplasm.